Cannabis extracts blocked multiple steps of atherosclerosis development in lab cells

Three cannabis extracts with different THC/CBD ratios all inhibited LDL oxidation, foam cell formation, and inflammatory pathway activation through non-traditional cannabinoid receptors.

Musetti, Bruno et al.·PloS one·2024·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-05579Animal StudyPreliminary Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Three extracts (high, intermediate, low THC/CBD) all inhibited LDL oxidation and foam cell formation (ED50 5-12 ug/mL). Effects independent of CB1/CB2, operating through TRPV1, TRPV4, GPR55 and calcium signaling. Decreased CD36 and OLR1 via NFkB inhibition.

Key Numbers

Three extracts tested. All inhibited LDL oxidation and foam cell formation. ED50: 5-12 ug/mL. Via TRPV1, TRPV4, GPR55, not CB1/CB2. NFkB pathway inhibition.

How They Did This

In vitro study testing three cannabis extracts against LDL oxidation, foam cell formation by J774 macrophages, and inflammatory signaling using receptor antagonists.

Why This Research Matters

Atherosclerosis is the leading cause of death. These findings identify phytocannabinoids as multi-target plaque formation inhibitors working through non-traditional pathways.

The Bigger Picture

Most cannabinoid research focuses on CB1/CB2 receptors. This reveals cardiovascular mechanisms through entirely different pathways.

What This Study Doesn't Tell Us

Entirely in vitro. Effective concentrations may not be achievable in vivo. Cannot predict human atherosclerosis outcomes.

Questions This Raises

  • ?Would oral cannabis achieve sufficient vascular concentrations?
  • ?Could targeted formulations provide cardiovascular protection without psychoactive effects?

Trust & Context

Key Stat:
cannabis extracts inhibited LDL oxidation, foam cell formation, and NFkB inflammation through TRPV and GPR55 receptors
Evidence Grade:
Mechanistically rigorous in vitro study but entirely cell-based with no in vivo data.
Study Age:
2024 publication.
Original Title:
Cannabis sativa extracts inhibit LDL oxidation and the formation of foam cells in vitro, acting as potential multi-step inhibitors of atherosclerosis development.
Published In:
PloS one, 19(12), e0310777 (2024)
Database ID:
RTHC-05579

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Can cannabis prevent heart disease?

This lab study found cannabis blocked plaque formation steps in cells. However, these are test-tube results. Some epidemiological studies actually link cannabis use to cardiovascular risks.

Why did all three extracts work?

The effects operated through non-canonical receptors, making the specific THC/CBD ratio less important for this effect.

Read More on RethinkTHC

Cite This Study

RTHC-05579·https://rethinkthc.com/research/RTHC-05579

APA

Musetti, Bruno; Kun, Alejandra; Menchaca, David; Rodríguez-Haralambides, Alejandra; Varela, Javier; Thomson, Leonor; Bahnson, Edward M. (2024). Cannabis sativa extracts inhibit LDL oxidation and the formation of foam cells in vitro, acting as potential multi-step inhibitors of atherosclerosis development.. PloS one, 19(12), e0310777. https://doi.org/10.1371/journal.pone.0310777

MLA

Musetti, Bruno, et al. "Cannabis sativa extracts inhibit LDL oxidation and the formation of foam cells in vitro, acting as potential multi-step inhibitors of atherosclerosis development.." PloS one, 2024. https://doi.org/10.1371/journal.pone.0310777

RethinkTHC

RethinkTHC Research Database. "Cannabis sativa extracts inhibit LDL oxidation and the forma..." RTHC-05579. Retrieved from https://rethinkthc.com/research/musetti-2024-cannabis-sativa-extracts-inhibit

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.